Synuclein is a protein that is found in abundance in neurons and is particularly enriched in presynaptic nerve terminals. Synaptic vesicle trafficking and ensuing neurotransmitter release are controlled by -synuclein. -synuclein has been linked to Parkinson's disease (PD) and other neurodegenerative diseases through genetic and neuropathology research. Multiple neurodegenerative diseases known as synucleinopathies are characterized by the accumulation of misfolded oligomers and larger aggregates of -synuclein, but the mechanisms by which -synuclein acts in neurodegeneration are unknown.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V70176 | (Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) | 1802518-63-3 | (Rac)-Minzasolmin ((Rac)-UCB0599) is a brain barrier-penetrating inhibitor that can suppress the accumulation of alpha-synuclein (ASYN) misfolding and aggregation. | |
V70190 | (S)-Minzasolmin ((S)-UCB0599; (S)-NPT200-11) | 1802518-91-7 | (S)-Minzasolmin is an enantiomer of Minzasolmin, an inhibitor (blocker/antagonist) of α-synuclein oligomerization. | |
V80156 | Brazilin-7-acetate | Brazilin-7-acetate (B-7-A) is an inhibitor (blocker/antagonist) of α-synuclein (α-Syn) aggregates. | ||
V70194 | D-685 | 2893801-00-6 | D-685, a prodrug of D-520, displays greater in vivo anti-PD/Parkinson's disease efficacy than parent D-520 in a lipidated animal model of PD/Parkinson's disease. | |
V94863 | GSD-16-24 | GSD-16-24 is a lead compound that binds directly to the C-terminal IDR of α-syn monomers and fibrils, thereby preventing fibrils from binding to the receptor. | ||
V87865 | LETC | LETC is an orally active inhibitor of α-synuclein (α-Syn) aggregation with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. | ||
V70179 | Minzasolmin (UCB0599; (R)-NPT200-11) | 1802518-92-8 | Minzasolmin is an inhibitor (blocker/antagonist) of alpha-synuclein oligomerization. | |
V3222 | ELN484228 | 312-63-0 | ELN484228, a phenyl-sulfonamide compound, is a cell-permeable blocker ofα-synucleinwhich is a key protein in Parkinson’s disease. | |
V87863 | NS163 | NS163 is an α-Synuclein aggregation antagonist. | ||
V70181 | PBT434 mesylate (ATH434 mesylate) | 2387898-69-1 | PBT434 methanesulfonate is a potent, orally bioactive, α-synuclein aggregation inhibitor that crosses the BBB (blood-brain barrier). | |
V87864 | PDpep1.3 | PDpep1.3 is a peptide inhibitor whose main activity is to disrupt the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). | ||
V70192 | Peucedanocoumarin III | 130464-57-2 | Peucedanocoumarin III is an α-synuclein and huntingtin aggregate inhibitor that enhances the clearance of nuclear and cytoplasmic β23 aggregates and protects against disease-associated proteins (i. | |
V87847 | PROTAC α-synuclein degrader 6 | 3032208-24-2 | PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader for α-synuclein and tau with EC50 of 1.57 μM and 4.09 μM, respectively. | |
V78513 | Sycosterol A | Sycosterol A is an alpha-synuclein (α-syn) sterol inhibitor. | ||
V70173 | SynuClean-D (SC-D) | 685121-45-3 | SynuClean-D (SC-D) is an inhibitor (blocker/antagonist) of alpha-synuclein aggregation that disrupts mature amyloid fibrils, prevents fibril multiplication, and eliminates dopamine in animal models of PD/Parkinson's disease Degeneration of neuronal neurons. | |
V87860 | Tat-βsyn-degron | 2816095-52-8 | Tat-βsyn-degron is an α-synuclein knockdown peptide. | |
V70180 | Utreloxastat (PTC857) | 1213269-96-5 | Utreloxastat (PTC857) is a compound utilized in the research of diseases including alpha-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemia-reperfusion-related injury. | |
V70189 | α-Synuclein (34-45) (human) | 2170181-52-7 | α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. | |
V70193 | α-Synuclein (45-54) (human) | 2243206-98-4 | α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. | |
V70188 | α-Synuclein (61-75) | 440645-08-9 | α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. |